

Project Consortium

- Software Cluster, c/o CyberForum e.V. (Germany)
- Cluster für Individualisierte ImmunIntervention e.V. (Germany)
- intelligent views GmbH (Germany)
- NETSYNO Software GmbH (Germany)
- Oslo Cancer Cluster S.A (Norway)
- Smart Innovation Norway (Norway)
- Oncotyrol - Center for Personalized Cancer Medicine GmbH (Austria)
- IT-Cluster - Business Upper Austria OÖ Wirtschaftsagentur GmbH (Austria)

Contact persons in Norway:



Jutta Heix

Oslo Cancer Cluster
email: jh@oslocancercluster.no
mobile: +47 941 63 089



Victoria Næss Jensen

Smart Innovation Norway
email: victoria.jensen@ncecmart.com
mobile: +47 418 48 343



D.B.R.K. Gupta Udatha

Oslo Cancer Cluster &
Smart Innovation Norway
email: gu@oslocancercluster.no
mobile: +47 455 34 627

Get funding for innovation partnerships to digitalize biopharmaceutical R&D

Advancing precision medicine in the digital age requires solutions developed in the IT and software sector, e.g. big data, machine learning, IT security, data protection, and cross-enterprise collaboration.

The PERMIDES project aims at bringing together SMEs (micro, small and medium-sized enterprises) from the biopharmaceutical and IT sector to advance precision medicine through the development of novel digital solutions along the biopharma value chain.

Biopharma SMEs participating in the innovation projects can increase competitiveness and benefit from an innovation voucher scheme that will provide up to **EUR 60,000** per SME.


Information on SME benefits, important dates, project funding, partners and contact details can be found at the project website:

<http://permides.eu/>



Personalised Medicine Innovation
through Digital Enterprise Solutions

Funding opportunities
for
Biopharma & IT Projects



Funded by the European Union's
Horizon 2020 programme under grant
agreement No 691546

PERMIDES - Open Call for Proposals for Financial Support

**Publication of
PERMIDES Call:**
March 15th, 2017

Evaluation Deadlines:
May 15th, August 31st
& November 15th, 2017

**Time from application to
project initiation:**
Up to 3 months

Maximum funding: Biopharma SMEs can avail benefits from this call for obtaining vouchers up to a maximum of € 60,000. IT SMEs can collaborate with various biopharma SMEs in multiple projects, and are not affected by € 60,000 limit. Please note that biopharma SMEs are the beneficiaries of the innovation projects and the costs involved in providing the services by IT SMEs will be funded and paid to IT SMEs by PERMIDES.

Maximum duration of the innovation projects: 6 months
All funded projects finalized by : June 15th, 2018

Web address for proposal submissions: <http://permides.eu/apply-now/>

Scope: Proposals should address innovation barriers and challenges of the biopharmaceutical value chain in the area of personalized medicine by means of digitalization solutions.

Target group: The voucher funding scheme of PERMIDES is aimed at SMEs from the biopharmaceutical sector developing novel personalized medicine products and solutions (e.g. biotech/medtech companies, diagnostics companies, CROs, biobank companies, bioinformatic companies). Only biopharma SMEs, together with IT SMEs, according to the EU definition and established in one of the EU Member States or Associated Countries can submit the proposals for funding provided by PERMIDES. To be eligible for funding, project teams need to consist of one biopharma SME as main applicant/beneficiary and at least one IT SME as service provider. Potential project team partners can be found via the PERMIDES platform offering the need-vs-expertise-based matchmaking of companies from the biopharmaceutical and IT sector.

Evaluation criteria: Proposals will be reviewed by a panel of PERMIDES consortium members and external experts based on the following criteria:

- Innovation Level
- Technical Feasibility
- Resource Capacities
- Partner Competence
- Fitness to Industry Needs